These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25355929)

  • 1. A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.
    Reiss KA; Herman JM; Zahurak M; Brade A; Dawson LA; Scardina A; Joffe C; Petito E; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Siu LL; Azad NS
    Clin Cancer Res; 2015 Jan; 21(1):68-76. PubMed ID: 25355929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
    Reiss KA; Herman JM; Armstrong D; Zahurak M; Fyles A; Brade A; Milosevic M; Dawson LA; Scardina A; Fischer P; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Stayner LA; Siu LL; Azad NS
    Gynecol Oncol; 2017 Mar; 144(3):486-490. PubMed ID: 28109627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
    Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
    Nishikawa T; Matsumoto K; Tamura K; Yoshida H; Imai Y; Miyasaka A; Onoe T; Yamaguchi S; Shimizu C; Yonemori K; Shimoi T; Yunokawa M; Xiong H; Nuthalapati S; Hashiba H; Kiriyama T; Leahy T; Komarnitsky P; Fujiwara K
    Cancer Sci; 2017 Sep; 108(9):1834-1842. PubMed ID: 28665051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
    Nishio S; Takekuma M; Takeuchi S; Kawano K; Tsuda N; Tasaki K; Takahashi N; Abe M; Tanaka A; Nagasawa T; Shoji T; Xiong H; Nuthalapati S; Leahy T; Hashiba H; Kiriyama T; Komarnitsky P; Hirashima Y; Ushijima K
    Cancer Sci; 2017 Nov; 108(11):2213-2220. PubMed ID: 28837250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
    Kummar S; Ji J; Morgan R; Lenz HJ; Puhalla SL; Belani CP; Gandara DR; Allen D; Kiesel B; Beumer JH; Newman EM; Rubinstein L; Chen A; Zhang Y; Wang L; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    Clin Cancer Res; 2012 Mar; 18(6):1726-34. PubMed ID: 22307137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
    Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
    Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
    Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
    Mehta MP; Wang D; Wang F; Kleinberg L; Brade A; Robins HI; Turaka A; Leahy T; Medina D; Xiong H; Mostafa NM; Dunbar M; Zhu M; Qian J; Holen K; Giranda V; Curran WJ
    J Neurooncol; 2015 Apr; 122(2):409-17. PubMed ID: 25682091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Thaker PH; Salani R; Brady WE; Lankes HA; Cohn DE; Mutch DG; Mannel RS; Bell-McGuinn KM; Di Silvestro PA; Jelovac D; Carter JS; Duan W; Resnick KE; Dizon DS; Aghajanian C; Fracasso PM
    Ann Oncol; 2017 Mar; 28(3):505-511. PubMed ID: 27998970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
    Pratz KW; Rudek MA; Gojo I; Litzow MR; McDevitt MA; Ji J; Karnitz LM; Herman JG; Kinders RJ; Smith BD; Gore SD; Carraway HE; Showel MM; Gladstone DE; Levis MJ; Tsai HL; Rosner G; Chen A; Kaufmann SH; Karp JE
    Clin Cancer Res; 2017 Feb; 23(4):899-907. PubMed ID: 27551000
    [No Abstract]   [Full Text] [Related]  

  • 15. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.